Sermorelin HSA/FSA Eligibility: What Women Need to Know Before Submitting

What Sermorelin Actually Is (and Why That Affects Your Benefits)

Sermorelin is a synthetic 29-amino-acid peptide that mimics growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to your pituitary to release growth hormone (GH). It does not supply GH directly. It nudges your own pituitary to produce more.

That distinction matters for benefits. The FDA approved sermorelin (brand name Geref) for GH deficiency in children, but manufacturing was voluntarily discontinued in 2008. Today, all sermorelin dispensed in the United States comes from 503A compounding pharmacies, which are licensed to prepare individualized prescriptions but whose products carry no FDA approval of their own. That compounded status is the single biggest reason HSA and FSA administrators sometimes push back on reimbursement claims.

Why Women Are Increasingly Prescribed Sermorelin

GH secretion is not static across a woman's life. Pulsatile GH release is strongly modulated by estrogen. Studies measuring 24-hour GH secretory profiles show that GH pulse amplitude falls significantly as estradiol declines in the menopausal transition, which may contribute to the body-composition shifts, sleep disruption, and fatigue many women notice in perimenopause and post-menopause.

Clinicians prescribe sermorelin off-label for women with symptoms consistent with relative GH insufficiency: visceral fat gain despite stable diet, non-restorative sleep, low IGF-1 on labs, and reduced lean mass. It also appears in protocols for women with PCOS who have disrupted GH-IGF-1 axis signaling, and occasionally in postpartum contexts where fatigue and body-composition changes are prominent.

The Compounding Pharmacy Problem for Benefits Claims

Because sermorelin comes from a compounding pharmacy, some FSA/HSA third-party administrators (TPAs) treat it the way they treat other compounded medications: eligible only if prescribed for a diagnosed medical condition (not general wellness), accompanied by documentation, and sometimes subject to manual review. A plan that auto-adjudicates a brand-name drug at the pharmacy counter may require a paper claim for a compounded peptide.

IRS Rules That Govern Whether Sermorelin Qualifies

The IRS does not publish a drug-by-drug eligible-expense list. The governing document is IRS Publication 502, which defines a qualifying medical expense as one that "diagnoses, cures, mitigates, treats, or prevents a specific disease or condition." Expenses for general health or wellness do not qualify.

This language is actually favorable for sermorelin when prescribed correctly. If your clinician documents a diagnosis, such as adult growth hormone deficiency (ICD-10 code E23.0) or another specific condition, the prescription moves from the "general wellness" column to the "medical treatment" column.

The Letter of Medical Necessity: Your Most Important Document

A Letter of Medical Necessity (LMN) is a clinician-authored letter that connects your specific diagnosis to sermorelin as the treatment. Most TPAs want to see:

• Your name and date of birth
• The ICD-10 diagnosis code (most commonly E23.0 for hypopituitarism/GHD, or the code matching your documented condition)
• The prescribed dose and frequency
• A brief clinical rationale (why this drug, why this patient)
• The prescribing clinician's name, credentials, NPI, and signature
• A statement that the treatment is not for general wellness

Without an LMN, many TPAs default to denial for compounded medications. Ask your WomanRx clinician for this letter at the time of your first prescription.

What Your Plan Administrator Actually Decides

The IRS sets the floor. Your plan document sets the ceiling. The IRS explicitly states that employers can restrict eligible expenses to a narrower list than Publication 502, which means two women on different employer-sponsored FSA plans may get different answers about the same drug.

Before spending money, call the member services number on the back of your benefits card and ask two specific questions:

1. "Are compounded medications eligible for reimbursement under my plan?"
2. "Is a Letter of Medical Necessity required for compounded peptide prescriptions?"

Document the representative's name and the call date. If they say yes by phone and deny the claim in writing, that record helps your appeal.

How to Submit a Sermorelin Claim Step by Step

Most compounding pharmacies do not have a direct-billing agreement with FSA/HSA debit card networks, which means your card may decline at the pharmacy checkout even if sermorelin is ultimately reimbursable on your plan. Pay out of pocket first, then submit a manual claim.

Step 1: Gather Your Documents

You need four things:

• The pharmacy receipt showing the drug name (sermorelin acetate), the date, the amount paid, and the pharmacy's name and address
• The prescription label (or a copy provided by the pharmacy)
• The Letter of Medical Necessity from your prescriber
• Your plan's claim form (download from your TPA's member portal)

Step 2: Submit the Claim

Most TPAs accept claims by online portal upload, mobile app photo, email, fax, or mail. Online portal is fastest. If mailing, send copies, not originals, and note that FSA claims generally must be submitted before your plan's run-out date, which is typically 90 days after the end of the plan year. HSA reimbursements have no deadline as long as the expense occurred after the HSA was opened.

Step 3: Handle a Denial

Denials for compounded drugs are common on first submission. The denial letter will cite a reason code. Common codes and responses:

• "Not an eligible expense": Appeal with Publication 502 language plus the LMN
• "No medical necessity documented": Submit or resubmit the LMN
• "Compounded drug not covered under plan document": Request a copy of the full plan document and look for compounded drug exclusions; if the exclusion is absent, appeal in writing

You have 180 days from the date of the denial to file an internal appeal under ERISA rules for employer-sponsored plans.

HSA vs. FSA: Which Works Better for Sermorelin?

Both accounts use pre-tax dollars, but they work differently in ways that matter for a drug like sermorelin.

| Feature | HSA | FSA | |---|---|---| | Eligibility requirement | Must be enrolled in a qualifying HDHP | Any employer who offers one | | Rollover | Unlimited | Up to $640 in 2025; $660 in 2026 (IRS limit) | | Reimbursement deadline | No deadline (keep receipts) | Plan run-out date (often 90 days post-plan-year) | | Who controls the account | You (portable) | Employer plan | | Best for sermorelin? | Yes, because you can reimburse yourself years later | Yes, but time the expense to avoid losing funds |

If you are in perimenopause and expect to use sermorelin for 12-24 months, the HSA is the cleaner vehicle because you can let receipts accumulate and reimburse yourself in a single year, which simplifies record-keeping. If you only have an FSA, time your first purchase to fall early in the plan year so you have the full year's benefit available.

Sermorelin Cost and Practical Ways to Pay Less

The average monthly cost of compounded sermorelin at a 300 mcg nightly dose ranges from approximately $150 to $350 per month, depending on the pharmacy, the base (bacteriostatic water vs. Other diluent), and whether you are purchasing vials or pre-filled syringes. Telehealth programs that include the consultation fee in a bundled subscription may show a higher sticker price but lower total cost of care.

HSA/FSA Is the Biggest Lever

If you contribute the 2026 HSA maximum of $4,300 for self-only coverage, every dollar of sermorelin you reimburse through that account saves you your marginal tax rate. For a woman in the 22% federal bracket, a $2,400 annual sermorelin cost effectively becomes $1,872 after the tax offset. That is not a coupon. That is a structural cost reduction.

Telehealth Bundle Pricing

Some telehealth providers, including WomanRx, bundle the prescriber consultation, pharmacy coordination, and ongoing monitoring into a monthly program fee. That fee structure can be more economical than paying separately for a specialty endocrinology visit ($200-$400), lab work (IGF-1 testing, $50-$150), and the drug. The consultation fee itself may also be HSA/FSA eligible as a medical expense under Publication 502.

Pharmacy Shopping

Because compounded sermorelin is not priced by insurance contracts, cost varies meaningfully across 503A pharmacies. Three variables to compare:

• Price per milligram (ask for the cost per vial and the concentration)
• Shipping cost and cold-chain handling fee
• Whether the pharmacy is in-network with your telehealth provider (affects quality oversight)

Dose Optimization

Your clinician may start you at 200 mcg nightly and adjust based on your IGF-1 response at 6-8 weeks. Some women respond well at 200 mcg and never need 300-500 mcg, which translates directly to lower monthly cost. Pushing for the highest available dose before checking labs is not good medicine, and it is not good budgeting.

Sex-Specific Physiology: How Hormonal Status Changes Sermorelin's Effects

This section matters because most sermorelin clinical research has been conducted in men or mixed-sex cohorts, with women representing a minority of subjects. That is an honest evidence gap. What follows distinguishes directly studied data from reasonable extrapolation.

Estrogen and GH Secretion (Directly Studied)

Estrogen amplifies GH pulse amplitude. Studies in pre-menopausal women show higher basal GH secretion and stronger pituitary response to GHRH compared with age-matched men. Post-menopausal women off hormone therapy show GH secretion patterns that resemble those of older men. Women on oral estrogen therapy may actually have blunted IGF-1 responses because oral estrogen undergoes first-pass hepatic metabolism that suppresses IGF-1 production, even when GH is elevated. This means your IGF-1 lab result may underestimate your actual GH output if you take oral estrogen, and your clinician should account for that when interpreting your labs.

The Menstrual Cycle and GH Response (Extrapolation with Limited Direct Data)

GH pulsatility varies across the menstrual cycle, with some evidence of higher GH pulse amplitude in the follicular phase. Whether this meaningfully changes the clinical response to sermorelin has not been formally studied. It is reasonable to expect some variability in how you feel week to week, particularly before and around ovulation versus the luteal phase, but this has not been characterized in sermorelin-specific trials.

Menopause and Perimenopause (Most Relevant Life Stage for This Drug)

The women most commonly prescribed sermorelin are in perimenopause or post-menopause. As estrogen falls, GH pulse amplitude drops and total 24-hour GH secretion declines. One study in the Journal of Clinical Endocrinology and Metabolism found that GH secretion in post-menopausal women was approximately 30% lower than in pre-menopausal women of similar BMI. Sermorelin does not replace estrogen, and the two are not equivalent interventions. Women who are appropriate candidates for menopausal hormone therapy should discuss that option alongside or separately from sermorelin, since restoring estrogen may itself partially restore GH pulsatility.

PCOS

Women with PCOS have documented abnormalities in the GH-IGF-1 axis. Research published in the Journal of Clinical Endocrinology and Metabolism found that women with PCOS show altered GH secretory dynamics and elevated IGF-1 bioavailability compared with weight-matched controls. This means the baseline IGF-1 target ranges used in non-PCOS populations may not apply directly. Sermorelin prescribing in women with PCOS requires careful lab interpretation, and there are no PCOS-specific sermorelin dosing guidelines as of 2026.

Pregnancy, Lactation, and Contraception: Required Reading

Sermorelin is contraindicated in pregnancy. If you are pregnant, trying to conceive, or breastfeeding, stop reading about cost savings and talk to your OB-GYN or MFM first.

Pregnancy

Sermorelin has no FDA-approved pregnancy category because it was discontinued before the newer labeling system took effect, and compounded sermorelin carries no manufacturer labeling at all. The FDA has not evaluated compounded sermorelin for safety in pregnancy. Animal studies with GHRH analogs have shown effects on fetal growth axis development, and the human data in pregnancy is essentially absent. The precautionary standard is: do not use sermorelin during pregnancy.

If you become pregnant while taking sermorelin, discontinue immediately and contact your obstetric provider.

Lactation

There are no published data on sermorelin transfer into human breast milk. The molecular weight of sermorelin (3,358 Da) suggests it is unlikely to transfer at clinically significant levels, but "unlikely" is not "studied and confirmed safe." Given the absence of lactation data, most clinicians advise discontinuing sermorelin while breastfeeding. Your decision should be made with your prescribing clinician and, if possible, a lactation medicine specialist.

Contraception

Women of reproductive age who are prescribed sermorelin should use reliable contraception throughout treatment. This is not because sermorelin is a known teratogen, but because the human pregnancy safety data simply does not exist. If you are trying to conceive, sermorelin should be discontinued before attempting pregnancy, not after a positive test.

Postpartum

The postpartum period involves significant hormonal shifts, including changes in GH secretion related to prolactin dominance and sleep deprivation. Sermorelin use in the postpartum period has not been studied. Postpartum fatigue and body-composition changes have many causes, and sermorelin is not a first-line intervention in this life stage.

Who Sermorelin Is Right For (and Who Should Look Elsewhere)

The following framework is based on clinical evidence and WomanRx editorial board consensus, offered to help you have a more specific conversation with your clinician. It is not a substitute for individualized medical advice.

Strong Candidates

• Post-menopausal women with documented low IGF-1 (age-adjusted reference range), non-restorative sleep, and visceral fat accumulation who are not candidates for or who have chosen not to use growth hormone replacement
• Peri-menopausal women with progressive loss of lean mass and fatigue unresponsive to optimization of sleep, nutrition, and hormone therapy
• Women with documented adult growth hormone deficiency (E23.0) confirmed by stimulation testing, where recombinant GH is cost-prohibitive

Moderate Candidates (Discuss Carefully)

• Women with PCOS and low IGF-1, given the altered GH axis in PCOS (careful lab interpretation required)
• Women in their reproductive years with significant GH insufficiency symptoms; use reliable contraception throughout
• Women on oral estrogen therapy: expect IGF-1 to underrepresent GH response; transdermal estrogen may give cleaner lab interpretation

Not Appropriate

• Pregnant or breastfeeding women
• Women trying to conceive
• Women with active malignancy or a history of hormone-sensitive cancer (GH stimulation in the setting of cancer has not been adequately studied for safety)
• Women with untreated hypothyroidism (thyroid hormone is required for normal GH signaling; treat the thyroid first)
• Women seeking general anti-aging effects without a documented clinical indication (this does not meet the IRS Publication 502 standard and is unlikely to be HSA/FSA reimbursable)

A Practical 2026 Checklist for HSA/FSA Sermorelin Reimbursement

Before you submit:

• [ ] Confirm your plan covers compounded medications (call member services, document the call)
• [ ] Request a Letter of Medical Necessity from your WomanRx clinician at the time of your first prescription
• [ ] Get your pharmacy receipt itemized with drug name, date, amount, and pharmacy details
• [ ] Download your plan's claim form from the member portal
• [ ] For FSA: check your plan-year run-out date; submit before the deadline
• [ ] For HSA: save your receipts even if you do not submit immediately; there is no deadline for reimbursement

If denied:

• [ ] Read the denial reason code
• [ ] File an internal appeal within 180 days (ERISA plans)
• [ ] Include Publication 502 language, your LMN, and any plan document language that does not explicitly exclude compounded drugs